Abstracts tagged "autoimmune diseases"

Abstract Number: 1667 • ACR Convergence 2020
Development of Autoimmune Diseases and HLA Associations in Children with Neonatal Lupus and Their Unaffected Siblings
Amit Saxena¹, Aaron Garza Romero², Daniel Gratch³, Peter Izmirly⁴, Hannah Ainsworth⁵, Miranda Marion⁵, Carl Langefeld⁶, Robert Clancy⁷ and Jill Buyon⁸, ¹NYU School of Medicine, New York, ²Gonzaba Medical Group, San Antonio, ³NYU Langone Health, New York, ⁴Department of Medicine, New York University School of Medicine, New York, NY, ⁵Wake Forest School of Medicine, Winston-Salem, ⁶Wake Forest School of Medicine, Winston Salem, NC, ⁷New York University School of Medicine, New York, NY, ⁸Department of Medicine, NYU School of Medicine, New York, NY
Background/Purpose: Neonatal Lupus (NL) is a model of passively acquired autoimmunity conferred by exposure to maternal anti-Ro antibodies with major manifestations being congenital heart block…
Abstract Number: PP03 • ACR Convergence 2020
Connecting with Rheumatology Professionals and Thought Leaders Inspired the Creation of a New Program Focused on Relapsing Polychondritis (“RP”), a Rare Rheumatic Disease: Participating at ACR Annual Meetings Has Provided Exceptional Opportunities to Learn and Build Relationships
Nancy Linn¹, Catherine Bammert², David Bammert³ and Michael Linn⁴, ¹Relapsing Polychondritis Foundation, Palos Verdes Estates, CA, ²MD Anderson, Houston, TX, ³Relapsing Polychondritis Foundation, Houston, TX, ⁴Relapsing Polychondritis Foundation, New York, NY
Background/Purpose: In 2011, I was diagnosed with relapsing polychondritis ("RP"), a debilitating and sometimes fatal rheumatic disease that is characterized by inflammation of cartilage and…
Abstract Number: 0016 • ACR Convergence 2020
Differential Characteristics in Inflammatory Rheumatologic Patients with Severe and Mild COVID-19 Infection
Paula García Escudero¹, Claudia Stoye², Orlando Pompei fernández², Marta González Fernández¹, Joaquín María Belzunegui Otano³, Juan Ramón De Dios², Belén Álvarez Rodríguez², Elena Garmendia Sánchez¹, Susana Gil², Ana Ruibal-Escribano⁴, Margarida Vasques Rocha², Francisco García Llorente⁵, César Antonio Egües⁶, Edurne Guerrero⁷ and Jaime Calvo-Alén², ¹Hospital Universitario Cruces, Barakaldo, Spain, ²Hospital Universitario Araba, Vitoria-Gasteiz, Pais Vasco, Spain, ³Rheumatology Service, Hospital Universitario Donostia. San Sebastián, Spain, San Sebastian, Spain, ⁴Hospital Alfredo Espinosa, Urduliz, Pais Vasco, Spain, ⁵Hospital Universitario de Galdakao, Galdakao, Pais Vasco, Spain, ⁶Hospital Universitario Donostia, Donostia-San Sebastián, Pais Vasco, Spain, ⁷Hospital Alto Deba, Arrasate, Pais Vasco, Spain
Background/Purpose: SARS COV 2 pandemic has been an issue which has challenged the health care systems around the world. Rheumatology has been involved in two…
Abstract Number: 0304 • ACR Convergence 2020
Type I Interferon Inhibits Glucocorticoid-Induced Leucine Zipper (GILZ) Expression and Upregulation by Glucocorticoids
Wendy Dankers¹, Melissa Northcott², Taylah Bennett³, Brendan Russ³, Jacqueline Flynn¹, Sarah Jones² and Eric Morand¹, ¹Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, ²Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia, ³Department of Microbiology, Monash University, Melbourne, Australia
Background/Purpose: Glucocorticoids (GC) are broadly used in the treatment of inflammatory diseases, including systemic lupus erythematosus (SLE). Despite their widespread use, most SLE patients do…
Abstract Number: 0560 • ACR Convergence 2020
Mortality Burden of Immune-Mediated Inflammatory Diseases (IMID): Race/Ethnicity, Sex, and Geographic Variation in the United States
Ram Singh¹, Eric Yen² and Meifang Wu², ¹UCLA David Geffen School of Medicine, Los Angeles, CA, ²UCLA, Los Angeles, CA
Background/Purpose: Almost every organ system can be affected by immune-mediated inflammatory diseases (IMID) characterized by inflammation and therapeutic response to immune-suppressive or anti-inflammatory drugs. Since…
Abstract Number: 0859 • ACR Convergence 2020
Biomarkers of B-cell Depletion and Response in a Randomized, Controlled Trial of Obinutuzumab for Proliferative Lupus Nephritis
Ed Vital¹, Philippe Remy², Luis Fernando Quintana Porras³, Laurent Chiche⁴, Dominique Chauveau⁵, Richard Furie⁶, Thomas Schindler⁷, Jay Garg⁸, Matthew Cascino⁸, Zahir Amoura⁹, Andrea Doria¹⁰, Cary Looney⁸ and Dario Roccatello¹¹, ¹University of Leeds; NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ²APHP Groupe Hospitalier Henri-Mondor, Creteil, France, ³Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, ⁴Hôpital Européen, Marseille, France, ⁵Hôpital Rangueil, Centre Hospitalier Univ de Toulouse, Toulouse, France, ⁶Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ⁷F. Hoffmann-La Roche Ltd., Basel, Switzerland, ⁸Genentech, Inc., South San Francisco, CA, ⁹Hôpital Pitié-Salpêtrière, Paris, ¹⁰University of Padua, Padua, Italy, ¹¹S Giovanni Hospital, Univ of Turin, Turin, Italy
Background/Purpose: Incomplete B-cell and plasmablast depletion, as measured using highly sensitive flow cytometry (HSFC), is associated with lower response rates following rituximab in SLE [1].…
Abstract Number: 1050 • ACR Convergence 2020
Rituximab in the Treatment of Interstitial Lung Disease Associated with Autoimmune Diseases: Experience from a Single Referral Center
Belén Atienza-Mateo¹, Sara Remuzgo-Martínez², Diana Prieto-Peña¹, Víctor Manuel Mora Cuesta³, David Iturbe-Fernández³, Sonia Fernández Rozas¹, Alfonso Corrales¹, José Manuel Cifrián² and Miguel Ángel González-Gay⁴, ¹Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic bone diseases of the musculoskeletal system, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic bone diseases of the musculoskeletal system, IDIVAL, Santander, Spain, ³Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic bone diseases of the musculoskeletal system, IDIVAL; and Department of Pneumology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain
Background/Purpose: The presence of interstitial lung disease (ILD) in patients with autoimmune diseases (AD)s influences significantly on their morbidity and mortality [1]. Different treatment strategies…
Abstract Number: 1297 • ACR Convergence 2020
Lupus Antibodies in Relation to Malignancy
Sarah Huse¹, Jim Oates², Gary Gilkeson³ and Diane Kamen¹, ¹Medical University of South Carolina, Charleston, SC, ²Medical University of South Carolina, Charleston, SC, Charleston, SC, ³Division of Rheumatology, Medical University of South Carolina, Charleston, SC
Background/Purpose: Systemic Lupus Erythematosus (SLE) a chronic inflammatory autoimmune disease that has the potential to affect every organ system. Studies have shown increased risk of…
Abstract Number: 1454 • ACR Convergence 2020
B Cell-specific TLR7 Regulates Lupus in TLR9 Deficient Mice
Haylee Baxendell¹, Minjung Kim², Jeremy Tilstra² and Mark Shlomchik², ¹University of Pittsburgh, Cranberry Twp, PA, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease that results in significant morbidity and mortality. In SLE, endosomal TLR7 and TLR9 are known to…
Abstract Number: 1697 • ACR Convergence 2020
Immune Related Adverse Events from Checkpoint Inhibitor Therapy: Survey of Hospitalists’ Awareness and Experiences
Cassandra Calabrese¹, Alexa Meara² and Varalakshmi Janamanchi¹, ¹Cleveland Clinic, Cleveland, OH, ²Ohio State University Wexner School of Medicine, Columbus, OH
Background/Purpose: The introduction of immunologic checkpoint inhibitor therapy (ICI) has caused a paradigm shift in the world of cancer treatment. Their use, however, is attended…
Abstract Number: PP04 • ACR Convergence 2020
My Multidisciplinary Healthcare Team and Patient Advocacy Groups Saved My Life
Tedi LaMere¹, Michael Linn² and David Bammert³, ¹Relapsing Polychondritis Foundation, Kalispell, MT, ²Relapsing Polychondritis Foundation, New York, NY, ³Relapsing Polychondritis Foundation, Houston, TX
Background/Purpose: I enjoyed being physically active my entire life – climbing mountains, hunting, and hiking. This drastically changed around 2012, when I noticed that I was…
Abstract Number: 147 • 2020 Pediatric Rheumatology Symposium
Familial Clustering of Immune-mediated Diseases in Children with Abrupt-onset OCD
Avis Chan ¹, Tiffany Phu ¹, Bahare Farhadian ², Theresa Willett ³, Melissa Silverman ¹, Paula Tran ¹, Margo Thienemann ³ and Jennifer Frankovich⁴, ¹Stanford University School of Medicine, Palo Alto, ²Stanford Immune Behavioral Health Clinic and PANS Research Program at Lucile Packard Children's Hospital, Palo Alto, ³Stanford University School of Medicine, Palo Alto, California, ⁴Stanford
Background/Purpose: Recent epidemiologic studies have reported increased rates of immune-mediated comorbidities among first-degree relatives of patients with OCD and tic disorders.(Mataix-Cols et al., Mol Psychiatry…
Abstract Number: L19 • 2019 ACR/ARP Annual Meeting
Ianalumab (VAY736), a Dual Mode of Action Biologic Combining BAFF Receptor Inhibition with B Cell Depletion, for Treatment of Primary Sjögren’s Syndrome: Results of an International Randomized, Placebo Controlled Dose Range Finding Study in 190 Patients
Simon Bowman¹, Robert Fox ², Thomas Dörner ³, Xavier Mariette ⁴, Athena Papas ⁵, Thomas Grader-Beck ⁶, Benjamin A. Fisher ⁷, Filipe Barcelos ⁸, Salvatore De Vita ⁹, Hendrik Schulze-Koops ¹⁰, Robert J. Moots ¹¹, Guido Junge ¹², Janice Woznicki ¹³, Monika Sopala ¹², Wen-Lin Luo ¹³ and Wolfgang Hueber ¹², ¹University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, ²Scripps Memorial Hospital and Research Institute, La Jolla, California, ³Charite Universitätsmedizin Berlin and DRFZ, Berlin, Germany, ⁴Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France, ⁵Tufts School of Dental Medicine, Massachusetts, ⁶Johns Hopkins University, Baltimore, ⁷University Hospitals Birmingham NHS Foundation Trust, Birmingham Biomedical Research Centre, Birmingham, United Kingdom, ⁸Nova Medical School, Hospital Cuf Descobertas, Instituto Português de Reumatologia,, Lisbon, Portugal, ⁹Rheumatology Clinic, Udine University Hospital, Department of Medical Area, University of Udine, Udine, Italy, Udine, Italy, ¹⁰Department of Rheumatology/Clinical Immunology, Ludwig-Maximilians-University Munich, Munich, Germany, ¹¹Institute of Ageing and Chronic Disease, Liverpool, United Kingdom, ¹²Novartis Pharma AG, basel, Switzerland, ¹³Novartis Pharmaceuticals Corporation, New Jersey
Background/Purpose: Primary Sjogren’s syndrome (pSS) is a multi-organ autoimmune disease primarily affecting excretory glands and characterized by B-cell hyperactivity. No approved systemic treatments are available.…
Abstract Number: 712 • 2019 ACR/ARP Annual Meeting
Safety and Tolerability of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease in the SENSCIS Trial: Subgroup Analysis Based on Demographic Characteristics
Oliver Distler¹, Kristin Highland ², Maureen Mayes ³, Masataka Kuwana ⁴, Lesley Saketkoo ⁵, Madelon Vonk ⁶, Michael Kreuter ⁷, Laura Hummers ⁸, Ute von Wangenheim ⁹, Martina Gahlemann ¹⁰, Veronika Kohlbrenner ¹¹, Margarida Alves ¹², Emmanuelle Clerisme-Beaty ¹² and Arata Azuma ¹³, ¹Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, ²Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH, ³Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX, ⁴Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Bunkyo-ku, Tokyo, Japan, ⁵New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans; Tulane University School of Medicine, University Medical Center – Comprehensive Pulmonary Hypertension Center, USA, New Orleans, ⁶Department of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands, Nijmegen, Gelderland, Netherlands, ⁷Center for Interstitial and Rare Lung Diseases, Pneumology, Thoraxklinik, University of Heidelberg, Member of the German Center for Lung Research, Germany, Germany, Germany, ⁸Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, USA, Baltimore, MD, ⁹Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany, Biberach an der Riss, ¹⁰Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Basel, Switzerland, ¹¹Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Ridgefield, ¹²Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ¹³Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan, Tokyo, Japan
Background/Purpose: In the SENSCIS trial in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), the adverse events associated with nintedanib were manageable for most patients…
Abstract Number: 2075 • 2019 ACR/ARP Annual Meeting
Cross-sectional Study and Mendelian Randomization Analysis of Diet in Six Prevalent Autoimmune Diseases
Antonio Julià¹, Sergio H Martinez ², Jesús Tornero ³, Juan Cañete ⁴, Antonio Fernández-Nebro ⁵, Francisco J. Blanco ⁶, Jesús Rodríguez ⁷, Francisco Javier Lopez-Longo ⁸, Benjamín Fernandez-Gutierrez ⁹, Jordi Gratacós ¹⁰, Jose J Pérez Venegas ¹¹, Carolina Pérez ¹², Ruben Queiró ¹³, Alejandro Olivé-Marqués ¹⁴, Mercedes Alperi-López ¹⁵, Carlos Montilla ¹⁶, José Luís Andreu ¹⁷, Juan Carlos Torre-Alonso ¹⁸, Mª Ángeles Aguirre-Zamorano ¹⁹, Hèctor Corominas ²⁰, Paloma Vela ²¹, Víctor Martínez-Taboada ²², Sara Marique ²³, Joan M Nolla ²⁴, Isidoro Gonzalez ²⁵, Santiago Muñoz-Fernandez ²⁶, José Luís Marenco de la Fuente ²⁷, Carlos González ²⁸, Antonio Zea ²⁹, Maria Lopez Lasanta ³⁰, Daniel Roig ³¹, Jose Maria Pego-Reigosa ³², Mireia Lopez Corbeto ³³, Pedro Zarco ³⁴, Mercedes Freire González ³⁵, Alba Erra ³⁶, Elvira Díez ³⁷, Santos Castañeda ³⁸, Esther Rodriguez ³⁹, Alicia García ⁴⁰, Patricia Carreira ³⁹, Georgina Salvador ⁴¹, Ricardo Blanco ⁴², Cesar Diaz-Torne ⁴³, Alfredo Willisch Domínguez ⁴⁴, Joan Antonio Mosquera ⁴⁵, Simón Sánchez-Fernández ⁴⁶, Júlio Ramírez ⁴⁷ and Sara Marsal ⁴⁸, ¹Rheumatology Research Group, Vall d’Hebron Hospital Research Institute, Barcelona, Spain., Barcelona, Catalonia, Spain, ²Hospital Vall d'Hebron, Barcelona, Barcelona, Spain, ³Hospital Universitario Guadalajara, Guadalajara, Spain., Guadalajara, Castilla-La Mancha, Spain, ⁴Rheumatology Department, Hospital Clínic and IDIBAPS,, Barcelona, Spain, ⁵Hospital Carlos Haya, Malaga, Spain, ⁶Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña, España, A Coruña, Spain, ⁷Hospital Universitario de Bellvitge, Hospitalet, Spain, ⁸Hospital Universitario Gregorio Marañón, Madrid, Madrid, Spain, ⁹Hospital Clínico San Carlos, Madrid, Madrid, Spain, ¹⁰Hospital Parc Taulí, Sabadell, Catalonia, Spain, ¹¹Hospital Jerez de la Frontera, Jerez de la Frontera, Spain, ¹²Parc de Salut Mar, Barcelona, Barcelona, Spain, ¹³Hospital Universitario Central de Asturias, Oviedo, Oviedo, Spain, ¹⁴Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain, ¹⁵Hospital Universitario Central de Asturias, Oviedo, Spain, ¹⁶Hospital Clínico Universitario de Salamanca, Salamanca, Spain, ¹⁷Hospital Puerta de Hierro, Madrid, Madrid, Spain, ¹⁸Hospital Monte Naranco, Oviedo, Spain, ¹⁹IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ²⁰Hospital de la Santa Creu i Sant Pau, Barcelona, Barcelona, Spain, ²¹Hospital General Universitario de Alicante, Alicante, Spain, ²²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²³Hospital Regional Univeristario de Málaga, Málaga, Spain, ²⁴Hospital Universitari de Bellvitge, Hospitalet, Spain, ²⁵Hospital Universitario La Princesa, Madrid, Spain, ²⁶Hospital Universitario Infanta Sofía, Madrid, Madrid, Spain, ²⁷Hospital Valme, Sevilla, Sevilla, Spain, ²⁸Hospital Universitario Gregorio Marañón, Madrid, Spain, ²⁹Hospital Universitario Ramón y Cajal, Madrid, Madrid, Spain, ³⁰Hospital Universitari Vall Hebrón, Barcelona, Barcelona, Catalonia, Spain, ³¹Hospital Moisès Broggi, Barcelona, Sant Joan Despí, Barcelona, Singapore, ³²Complexo Hospitalario Universitario, Vigo, Spain, ³³Hospital Universitari Vall d'Hebron, Barcelona, Catalonia, Spain, ³⁴Hospital Universitario Fundación Alcorcón, Madrid, Madrid, Spain, ³⁵Hospital Universitario Juan Canalejo, La Coruña, Spain, ³⁶H Sant Rafael, Barcelona, Barcelona, Spain, ³⁷Complejo Asistencial Universitario de León, León, Castilla y Leon, Spain, ³⁸Rheumatology, Hospital Universitario La Princesa, Madrid, Madrid, Spain, ³⁹Hospital Universitario 12 de Octubre, Madrid, Spain, ⁴⁰Centro de Salud Virgen de los Reyes, Sevilla, Sevilla, Spain, ⁴¹Hospital Mútua Terrassa, Terrassa, Spain, ⁴²Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, ⁴³Hospital de la Santa Creu i Sant Pau, barcelona, Catalonia, Spain, ⁴⁴Complexo Hospitalario de Ourense, Ourense, Spain, ⁴⁵Complejo Hospitalario Hospital Provincial de Pontevedra, Pontevedra, Spain, ⁴⁶Hospital La Mancha Centro, Alcázar de San Juan, Alcázar de San Juan, Spain, ⁴⁷Hospital Clínic de Barcelona, Barcelona, Spain, ⁴⁸Vall d’Hebron Hospital, Barcelona, Catalonia, Spain
Background/Purpose: Autoimmune diseases (AD) are complex diseases associated with both genetic and environmental risk factors. In the last 10 years major advances have been made…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].